SK Biopharmaceuticals stays in deficit during Q2


On Thursday, SK Biopharmaceuticals Co. revealed its net loss for the second quarter of 23.3 billion won (US$17.7 million), persisting in the red compared to the same period in the previous year.

The firm mentioned in a regulatory filing that its operating loss for the April-June period was 18.9 billion won, compared to a loss of 40.1 billion won the year prior. Revenue, however, increased 44.1 percent to 77 billion won.

The operating loss was 249.6 percent above the average forecast according to a survey by Yonhap Infomax, the financial data firm of Yonhap News Agency.

You might also like
Open chat
Need help?
Scan the code
Hello 👋
Can we help you?

Mark Silaev
Glosema Account Manager